Artivion - Public Comps and Valuation Multiples

Artivion Overview

About Artivion

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company’s products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

Founded

1984

HQ

Employees

1.6K+

Website

artivion.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $399M

LTM EBITDA $75.2M

EV

$1.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Artivion Financials

Artivion has a last 12-month revenue of $399M and a last 12-month EBITDA of $75.2M.

In the most recent fiscal year, Artivion achieved revenue of $389M and an EBITDA of $51.0M.

Artivion expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Artivion valuation multiples based on analyst estimates

Artivion P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$354M	$389M	XXX	XXX	XXX
Gross Profit	$203M	$229M	XXX	XXX	XXX
Gross Margin	57%	59%	XXX	XXX	XXX
EBITDA	$26.8M	$51.0M	XXX	XXX	XXX
EBITDA Margin	8%	13%	XXX	XXX	XXX
Net Profit	-$19.2M	-$30.7M	XXX	XXX	XXX
Net Margin	-5%	-8%	XXX	XXX	XXX
Net Debt	$269M	$248M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Artivion Stock Performance

As of April 15, 2025, Artivion's stock price is $23.

Artivion has current market cap of $987M, and EV of $1.3B.

See Artivion trading valuation data

Artivion Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.3B	$987M	XXX	XXX	XXX	XXX	$-0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Artivion Valuation Multiples

As of April 15, 2025, Artivion has market cap of $987M and EV of $1.3B.

Artivion's trades at 3.3x LTM EV/Revenue multiple, and 17.2x LTM EBITDA.

Analysts estimate Artivion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Artivion and 10K+ public comps

Artivion Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$1.3B	XXX	XXX	XXX
EV/Revenue	3.3x	XXX	XXX	XXX
EV/EBITDA	25.4x	XXX	XXX	XXX
P/E	-73.9x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	117.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Artivion Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Artivion Valuation Multiples

Artivion's NTM/LTM revenue growth is 10%

Artivion's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Artivion's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Artivion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Artivion and other 10K+ public comps

Artivion Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	10%	XXX	XXX	XXX	XXX
EBITDA Margin	13%	XXX	XXX	XXX	XXX
EBITDA Growth	90%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	23%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.2M	XXX	XXX	XXX	XXX
Opex per Employee	$0.1M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	7%	XXX	XXX	XXX	XXX
Opex to Revenue	54%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry